Goldsmith and colleagues (24) recently published data from a phase 1 clinical trial (NANT2015-02) with lorlatinib monotherapy in relapsed or refractory ALK-driven neuroblastoma, showing an overall response rate of 30% in children and 67% in adults. The gene discussed is ALK; the disease is neuroblastoma.